Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis

Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.

Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.